Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

Blood (2024) 144 (Supplement 1): 970.

https://doi.org/10.1182/blood-2024-202365

Published: 2024

Journal Articles

Comparative Proteomic Profiling of Multiple Myeloma (MM) Cell Lines Identifies Mitochondrial Dysfunction As a Marker of Resistance to Proteasome Inhibitors (PIs) with Potential Therapeutic Implications for BH3-Mimetics

Tadeusz Kubicki, Kinga Bednarek, Magdalena Kostrzewska-Poczekaj, Magdalena Luczak, Lydia Visser, Monique Lodewijk, Krzysztof Żyłka, Lidia Gil, Małgorzata Jarmuż-Szymczak, Dominik Dytfeld

Blood (2024) 144 (Supplement 1): 6821.

https://doi.org/10.1182/blood-2024-203854

Published: 2024

Journal Articles

Analysis of hTERT Gene Polymorphism, hTERT Gene Methylation and Telomere Length in Patients with De Novo AML, AML-MR and AML-Pct with Complex and Normal Karyotype

Monika Adamska, Ewelina Kowal-Wiśniewska, Anna Przybylowicz-Chalecka, Emilia Lis-Tanaś, Małgorzata Jarmuż-Szymczak, Lidia Gil

Blood (2024) 144 (Supplement 1): 6139.

https://doi.org/10.1182/blood-2024-207018

Published: 2024

Journal Articles

Acalabrutinib in Patients with Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Subjected to Allogeneic Hematopoietic Stem Cell Transplantation. a Phase 2 Study By the Polish Lymphoma Research Group

Sebastian Giebel, Anna Czyz, Iwona Hus, Lidia Gil, Krzysztof Giannopoulos, Joanna Romejko-Jarosinska, Maciej Majcherek, Agnieszka Szeremet, Anna Wache, Paulina Kwasnik, Wlodzimierz Mendrek, Wojciech Jurczak

Blood (2024) 144 (Supplement 1): 1660.

https://doi.org/10.1182/blood-2024-209931

Published: 2024

Journal Articles

The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia - a Report of Polish Adult Leukemia Group (PALG)

Blood (2024) 144 (Supplement 1): 4268.

https://doi.org/10.1182/blood-2024-203488

Published: 2024

Journal Articles

MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: First Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)

Blood (2024) 144 (Supplement 1): 3242.

https://doi.org/10.1182/blood-2024-201076

Published: 2024

Journal Articles

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Blood (2024) 144 (9): 955–963.

https://doi.org/10.1182/blood.2024024041

Published: 2024

Includes: Supplemental data

Journal Articles

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Blood (2023) 142 (Supplement 1): 4715.

https://doi.org/10.1182/blood-2023-189850

Published: 2023

Journal Articles

Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Lenalidomide Alone

Blood (2023) 142 (Supplement 1): 3344.

https://doi.org/10.1182/blood-2023-189537

Published: 2023

Journal Articles

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

Blood (2023) 142 (Supplement 1): 340.

https://doi.org/10.1182/blood-2023-190209

Published: 2023

Journal Articles

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) - the Polish Adult Leukemia Group AML-1/2018 Study

Agnieszka Wierzbowska, Agnieszka Pluta, Piotr Stelmach, Kamil Brzozowski, Magdalena Czemerska, Marta Sobas, Justyna Rybka, Tomasz Wróbel, Ewa Zarzycka, Witold Prejzner, Jan M. Zaucha, Andrzej Szczepaniak, Lidia Gil, Sebastian Giebel

Blood (2023) 142 (Supplement 1): 5914.

https://doi.org/10.1182/blood-2023-181633

Published: 2023

Journal Articles

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Blood (2022) 140 (Supplement 1): 9013–9015.

https://doi.org/10.1182/blood-2022-166184

Published: 2022

Journal Articles

Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Blood (2022) 140 (Supplement 1): 7747–7749.

https://doi.org/10.1182/blood-2022-167407

Published: 2022

Journal Articles

Prognostic Impact of Persistent Measurable Residual Disease in Patients with Acute Myeloid Leukemia FLT3+ Treated with Intensive Chemotherapy Plus Midostaurin - a Retrospective Study of the Polish Adult Leukemia Group (PALG)

Blood (2022) 140 (Supplement 1): 11836–11837.

https://doi.org/10.1182/blood-2022-170126

Published: 2022

Journal Articles

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) a Study of the Polish Adult Leukemia Group (AML-1/2018): Preliminary Results of the Dose Escalation Stage

Agnieszka Wierzbowska, Agnieszka Pluta, Piotr Stelmach, Marta Anna Sobas, Justyna Rybka, Tomasz Wróbel, Ewa Zarzycka, Witold Prejzner, Jan Zaucha, Andrzej Szczepaniak, Lidia Gil, Sebastian Giebel

Blood (2022) 140 (Supplement 1): 6165–6166.

https://doi.org/10.1182/blood-2022-163109

Published: 2022

Journal Articles

Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study

Blood (2022) 140 (Supplement 1): 6241–6243.

https://doi.org/10.1182/blood-2022-156950

Published: 2022

Journal Articles

A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL - a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)

Blood (2022) 140 (Supplement 1): 3206–3207.

https://doi.org/10.1182/blood-2022-166227

Published: 2022

Journal Articles

The Significance of Chromosome 11 Abnormalities in Patients with AML

Anna Przybylowicz-Chalecka, Joanna Czerwinska-Rybak, Blazej Ratajczak, Zuzanna Kandula, Andrzej Szczepaniak, Malgorzata Jarmuz-Szymczak, Lidia Gil

Blood (2021) 138 (Supplement 1): 4451.

https://doi.org/10.1182/blood-2021-152308

Published: 2021

Journal Articles

The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 Study

Blood (2021) 138 (Supplement 1): 3453.

https://doi.org/10.1182/blood-2021-153520

Published: 2021

Journal Articles

Clinical Outcome of t-AML with Respect to Genetic Abnormalities and Treatment Intensity - Single Center Analysis over the Past Two Decades

Monika Adamska, Ewelina Kowal-Wisniewska, Marta Baranska, Anna Przybylowicz-Chalecka, Anna Lojko-Dankowska, Monika Joks, Zuzanna Kandula, Malgorzata Jarmuz-Szymczak, Lidia Gil

Blood (2021) 138 (Supplement 1): 1222.

https://doi.org/10.1182/blood-2021-152239

Published: 2021

NARROW

A Polish Adult Leukemia Group (PALG) Prospective International Randomized Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016) - Topline Results

Comparative Proteomic Profiling of Multiple Myeloma (MM) Cell Lines Identifies Mitochondrial Dysfunction As a Marker of Resistance to Proteasome Inhibitors (PIs) with Potential Therapeutic Implications for BH3-Mimetics

Analysis of hTERT Gene Polymorphism, hTERT Gene Methylation and Telomere Length in Patients with De Novo AML, AML-MR and AML-Pct with Complex and Normal Karyotype

Acalabrutinib in Patients with Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia Subjected to Allogeneic Hematopoietic Stem Cell Transplantation. a Phase 2 Study By the Polish Lymphoma Research Group

The Experience of Commercially Available CPX-351 Use As First-Line Treatment for Patients with Acute Myeloid Leukemia - a Report of Polish Adult Leukemia Group (PALG)

MRD-Driven Venetoclax and Rituximab Combination in Previously Untreated Chronic Lymphocytic Leukemia: First Results of the Prospective, Multicenter, Phase II Trial of the Polish Adult Leukemia Group (VERITA PALG-CLL5)

Mass spectrometry–based assessment of M protein in peripheral blood during maintenance therapy in multiple myeloma

Longitudinal Assessment of Minimal Residual Disease (MRD) in the ATLAS Randomized Phase 3 Trial of Post-Transplant Treatment with Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Versus Lenalidomide (R) Alone in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Health-Related Quality of Life in Polish Patients with Multiple Myeloma Treated in the Phase 3 ATLAS Trial of Post-Transplant Maintenance with Carfilzomib, Lenalidomide, Dexamethasone or Lenalidomide Alone

Mass Spectrometry-Based Assessment of M-Protein in Peripheral Blood during Maintenance Therapy in Multiple Myeloma (MM) in the Phase III ATLAS Trial

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) - the Polish Adult Leukemia Group AML-1/2018 Study

A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Prognostic Impact of Persistent Measurable Residual Disease in Patients with Acute Myeloid Leukemia FLT3+ Treated with Intensive Chemotherapy Plus Midostaurin - a Retrospective Study of the Polish Adult Leukemia Group (PALG)

A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) a Study of the Polish Adult Leukemia Group (AML-1/2018): Preliminary Results of the Dose Escalation Stage

Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study

A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL - a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)

The Significance of Chromosome 11 Abnormalities in Patients with AML

The Prognostic Value of Early Measurable Residual Disease Assessment in Patients with Acute Myeloid Leukemia Treated with Intensive Chemotherapy - Preliminary Results of Polish Adult Leukemia Group PALG-AML1/2016 Study

Clinical Outcome of t-AML with Respect to Genetic Abnormalities and Treatment Intensity - Single Center Analysis over the Past Two Decades

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only